Modality
Degrader
MOA
KRASG12Di
Target
MDM2
Pathway
RNA Splicing
WilmsPTSDWet AMD
Development Pipeline
Preclinical
~Aug 2015
→ ~Nov 2016
Phase 1
Feb 2017
→ Feb 2027
Phase 1Current
NCT06904770
287 pts·Wet AMD
2017-02→2027-02·Recruiting
287 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-02-1711mo awayPh2 Data· Wet AMD
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
P1/2
Recruit…
Catalysts
Ph2 Data
2027-02-17 · 11mo away
Wet AMD
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06904770 | Phase 1/2 | Wet AMD | Recruiting | 287 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 | |
| SRP-1135 | Sarepta | Phase 2/3 | MDM2 |